PRDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pardes Biosciences's Enterprise Value is $-19.25 Mil. Pardes Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-82.88 Mil. Therefore, Pardes Biosciences's EV-to-EBIT ratio for today is 0.23.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Pardes Biosciences's Enterprise Value is $-19.25 Mil. Pardes Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-82.88 Mil. Therefore, Pardes Biosciences's EV-to-EBITDA ratio for today is 0.23.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Pardes Biosciences's Enterprise Value is $-19.25 Mil. Pardes Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, Pardes Biosciences's EV-to-Revenue ratio for today is .
The historical data trend for Pardes Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Enterprise Value | - | 660.57 | -96.71 |
Pardes Biosciences Quarterly Data | ||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Enterprise Value | Get a 7-Day Free Trial | -50.60 | -99.69 | -96.71 | -90.76 | -43.88 |
For the Biotechnology subindustry, Pardes Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Pardes Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Pardes Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
Enterprise Value (A: Dec. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 100.627163 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0 | + | 0 | - | 197.34 |
= | -96.71 |
Pardes Biosciences's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as
Enterprise Value (Q: Jun. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 109.318389 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0 | + | 0 | - | 153.197 |
= | -43.88 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences (NAS:PRDS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Pardes Biosciences's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -19.252 | / | -82.881 | |
= | 0.23 |
Pardes Biosciences's current Enterprise Value is $-19.25 Mil.
Pardes Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.88 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Pardes Biosciences's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | -19.252 | / | -82.881 | |
= | 0.23 |
Pardes Biosciences's current Enterprise Value is $-19.25 Mil.
Pardes Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.88 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Pardes Biosciences's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -19.252 | / | 0 | |
= |
Pardes Biosciences's current Enterprise Value is $-19.25 Mil.
Pardes Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pardes Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Fs Development Holdings Ii, Llc | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Opportunity Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Sean P. Brusky | officer: Chief Commercial Officer | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Thomas G Wiggans | director, officer: Chief Executive Officer | |
Foresite Capital Management V, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Pottage John C Jr | director | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Alsup Laurie Smaldone | director | 190 WOOSAMONSA RD, PENNINGTON NJ 08534 |
Heidi Henson | officer: Chief Financial Officer | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Brian Philippe Tinmouth | officer: Chief Business & Strategy Ofcr | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Brian Kearney | officer: Chief Development Officer | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Lee D Arnold | officer: Chief Scientific Officer | C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013 |
Uri A Lopatin | director, officer: President and CEO | C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013 |
From GuruFocus
By Marketwired • 08-14-2023
By Value_Insider Value_Insider • 11-07-2022
By Business Wire • 08-07-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
By sperokesalga sperokesalga • 02-21-2023
By Business Wire • 08-28-2023
By Marketwired • 07-17-2023
By Stock market mentor Stock market mentor • 02-01-2023
By Business Wire • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.